tiprankstipranks
Trending News
More News >
Tycoon Group Holdings Limited (HK:3390)
:3390
Hong Kong Market
Advertisement

Tycoon Group Holdings Limited (3390) AI Stock Analysis

Compare
1 Followers

Top Page

HK:3390

Tycoon Group Holdings Limited

(3390)

Rating:45Neutral
Price Target:
HK$0.50
▲(35.14%Upside)
The stock's overall score is primarily impacted by weak technical analysis and financial performance. The company faces significant challenges with cash flow and income stability. High leverage and declining profitability further contribute to the risk profile. While the high dividend yield offers potential appeal, it is overshadowed by concerns about financial health and stock price momentum.

Tycoon Group Holdings Limited (3390) vs. iShares MSCI Hong Kong ETF (EWH)

Tycoon Group Holdings Limited Business Overview & Revenue Model

Company DescriptionTycoon Group Holdings Limited (3390) is a Hong Kong-based investment holding company primarily engaged in the distribution and retail of healthcare and personal care products. The company operates through various segments, including proprietary Chinese medicine, health supplements, and personal care products. Tycoon Group Holdings Limited leverages both online and offline channels to distribute its products, aiming to meet the diverse health and wellness needs of its customers.
How the Company Makes MoneyTycoon Group Holdings Limited generates revenue through its diverse portfolio of healthcare and personal care products, which are distributed via multiple channels including retail chains, e-commerce platforms, and direct sales. The company capitalizes on its strong distribution network and strategic partnerships with major healthcare brands to ensure a broad market reach. Revenue streams include sales from proprietary Chinese medicines, health supplements, and a variety of personal care items. Additionally, the company benefits from economies of scale and extensive market knowledge, which help optimize its supply chain and enhance profitability.

Tycoon Group Holdings Limited Financial Statement Overview

Summary
Tycoon Group Holdings Limited exhibits a mixed financial profile with moderate weaknesses in income and cash flow statements. Though there are some strengths in the balance sheet, notably asset growth, the volatility in income and cash flow raises concerns about the company's financial health and operational efficiency.
Income Statement
55
Neutral
The income statement shows fluctuating performance over the past years. The gross profit margin has been relatively stable, but recent declines in revenue growth and net profit margins are concerns. The company has struggled to maintain consistent profitability, with recent net income levels significantly lower compared to past years. This volatility indicates potential challenges in revenue and cost management.
Balance Sheet
60
Neutral
The balance sheet reflects moderate stability with a relatively balanced debt-to-equity ratio, but there is a noticeable increase in total debt over the years, raising leverage concerns. Stockholders' equity has been increasing, which is a positive sign, but the equity ratio has been inconsistent. The company's assets have grown, but liabilities have increased at a faster rate, which could pose risks if not managed properly.
Cash Flow
45
Neutral
Cash flow analysis indicates significant challenges, particularly with operating cash flow being negative in several years. Free cash flow has also been erratic, with recent negative figures suggesting cash management issues. The operating cash flow to net income ratio indicates inefficiencies in converting income into cash. The company needs to focus on improving cash flow stability to mitigate financial stress.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue876.04M1.20B1.19B888.87M505.99M
Gross Profit232.66M321.10M243.53M135.01M71.06M
EBITDA35.85M356.41M85.26M5.45M-49.05M
Net Income3.24M297.32M43.75M-18.82M-61.13M
Balance Sheet
Total Assets1.01B988.95M1.01B881.46M619.91M
Cash, Cash Equivalents and Short-Term Investments34.02M39.10M74.60M71.63M119.34M
Total Debt330.98M206.16M341.60M239.08M198.32M
Total Liabilities516.61M445.40M718.96M620.20M329.47M
Stockholders Equity478.85M536.23M293.64M257.92M288.16M
Cash Flow
Free Cash Flow-78.94M7.97M-64.48M-50.11M-119.41M
Operating Cash Flow-76.62M11.86M-63.03M-42.20M-107.97M
Investing Cash Flow48.55M45.70M-16.61M-26.25M-74.95M
Financing Cash Flow25.62M-92.36M86.11M20.35M251.96M

Tycoon Group Holdings Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.37
Price Trends
50DMA
0.39
Negative
100DMA
1.46
Negative
200DMA
2.49
Negative
Market Momentum
MACD
-0.02
Negative
RSI
42.64
Neutral
STOCH
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3390, the sentiment is Neutral. The current price of 0.37 is above the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.39, and below the 200-day MA of 2.49, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 42.64 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3390.

Tycoon Group Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$357.83M7.546.61%9.43%-3.59%4.81%
68
Neutral
HK$431.20M6.1412.35%5.00%11.56%21.20%
61
Neutral
HK$410.40M32.572.03%-39.05%-80.60%
60
Neutral
HK$17.07B6.10-7.44%2.88%11.55%-28.15%
59
Neutral
HK$410.00M7.908.82%2.19%-10.82%-44.11%
51
Neutral
HK$319.16M0.321417.08%-20.01%
45
Neutral
HK$330.78M88.100.64%18.92%-26.91%-98.72%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:3390
Tycoon Group Holdings Limited
0.37
-3.43
-90.26%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.14
0.10
250.00%
HK:1643
Modern Chinese Medicine Group Co. Ltd.
0.65
0.31
91.18%
HK:1612
Vincent Medical Holdings Limited
0.66
0.30
83.33%
HK:1518
New Century Healthcare Holding Co. Ltd.
0.82
-0.02
-2.38%
HK:1110
Kingworld Medicines Group Ltd.
0.57
0.07
14.00%

Tycoon Group Holdings Limited Corporate Events

Tycoon Group Holdings Limited Updates Nomination Committee Terms
Jun 30, 2025

Tycoon Group Holdings Limited has announced amendments to the terms of reference for its Nomination Committee, effective from July 1, 2025. These changes emphasize diversity and independence within the committee, requiring a minimum of three members, the majority being independent non-executive directors, and at least one member of a different gender. This move is likely to enhance the company’s governance practices and strengthen its commitment to diversity and independent oversight, potentially impacting its reputation positively among stakeholders.

Tycoon Group Holdings Limited Announces Board Restructuring
Jun 30, 2025

Tycoon Group Holdings Limited has announced changes to its board of directors, effective from July 1, 2025. The company, which is incorporated in the Cayman Islands, has appointed Mr. Wong Ka Chun Michael as the Chairman and Chief Executive Officer. The board will also include a mix of non-executive and independent non-executive directors, each serving on various committees such as Audit, Remuneration, Nomination, and Corporate Governance. This restructuring is likely to impact the company’s governance and strategic direction, potentially influencing its market positioning and stakeholder relations.

Tycoon Group Announces Board Changes with New Appointments
Jun 13, 2025

Tycoon Group Holdings Limited has announced changes in its board of directors, with the resignation of Mr. Hu Yang as a non-executive director due to work adjustments, effective July 1, 2025. The company has appointed Mr. Ng Kwan Ho and Mr. Cao Ran as non-executive directors, also effective from July 1, 2025. Mr. Ng brings extensive experience in marketing and brand management, having held senior positions in various companies, including JBM (Healthcare) Limited and Amway Hong Kong Limited. These changes are expected to bring new perspectives and expertise to the company’s board, potentially impacting its strategic direction and market positioning.

Tycoon Group Secures Unanimous Approval at AGM
May 30, 2025

Tycoon Group Holdings Limited announced that all resolutions proposed at its Annual General Meeting on 30 May 2025 were approved by shareholders. The resolutions included the re-election of directors, adoption of new articles of association, and granting of mandates for share repurchase and issuance. This unanimous approval reflects strong shareholder support and positions the company for strategic flexibility in its operations.

Tycoon Group Sets Fixed Term for Distribution Agreements with Europharm and Jacobson Medical
May 29, 2025

Tycoon Group Holdings Limited has entered into supplemental agreements with Europharm and Jacobson Medical to establish a fixed period ending on 31 March 2028 for their distribution agreements. The proposed annual caps for the purchase of products under these agreements have been set, and the transactions are subject to annual review and disclosure requirements under the Listing Rules, but are exempt from certain approval requirements.

Tycoon Group Completes Share Issuance and Establishes New Shareholder Connections
May 22, 2025

Tycoon Group Holdings Limited has completed the issuance of 94,000,000 shares under a general mandate at an issue price of HK$0.5 per share, with the completion taking place on May 22, 2025. This transaction has resulted in the Subscriber, an indirect wholly-owned subsidiary of Jacobson Pharma, becoming a substantial shareholder with a 16.84% stake in the company, thus establishing new connected person relationships and ongoing connected transactions under the Listing Rules.

Tycoon Group Announces Share Issue to Boost Financial Stability
May 20, 2025

Tycoon Group Holdings Limited announced a proposed issue of shares under a general mandate, aiming to raise approximately HK$46.7 million. The proceeds are intended for general working capital, including inventory purchases, logistics, marketing, and other operational needs. The subscription price is set at a premium, reflecting confidence in the company despite recent financial challenges. This move is expected to strengthen the company’s financial position, reduce debt-to-equity ratio, and enhance stakeholder confidence, especially following a recent forced-sale event.

Tycoon Group Expands Southeast Asian Market and E-commerce Operations
May 19, 2025

Tycoon Group Holdings Limited has announced supplemental information regarding its continuing connected transactions, focusing on the 2025 Master Sale and Purchase Agreement with Talent Smart Group. The company anticipates increased purchases of Talent Smart Products due to the launch of 24 new products and the expansion of its distribution channels in Southeast Asia and e-commerce platforms in the PRC. The reinstatement of Combo Win Asia Limited as a wholly-owned subsidiary is expected to enhance the company’s e-commerce capabilities, potentially boosting sales and market reach.

Tycoon Group Holdings Limited Announces Share Subscription to Fuel Growth
Apr 29, 2025

Tycoon Group Holdings Limited has entered into a Subscription Agreement to issue 94,000,000 shares at HK$0.5 each, representing approximately 11.75% of its current issued share capital. The proceeds, estimated at HK$46.7 million after expenses, will be used to invest in core business growth and improve supply chain and logistics operations, positioning the company for expansion.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 04, 2025